Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Sangamo Therapeutics First Quarter 2026 Teleconference Call. Please be advised that today's conference is being recorded.
Sangamo Therapeutics Inc (SGMO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 0 | $0 | 0% | |
| 2. | Luminus Management Jonathan Barrett And Paul Segal | 0 | $0 | 0% | |
| 3. | MAK Capital One Michael Kaufman | 0 | $0 | 0% | |
| 4. | Ikarian Capital Neil Shahrestani | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.69 | 6,784 | $25,028.89 | 32,484 | 2022-06-03 | Filing | |
| $3.60 | 5,000 | $17,996.00 | 48,700 | 2022-06-01 | Filing | |
| $5.20 | 3,000 | $15,585.00 | 13,000 | 2020-03-18 | Filing | |
| $4.99 | 5,000 | $24,950.00 | 30,000 | 2020-03-17 | Filing | |
| $5.67 | 5,000 | $28,350.00 | 25,000 | 2020-03-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.25 | 69,827 | $17,694.16 | 115,284 | 2026-04-22 | Filing | |
| $0.26 | 345,942 | $89,183.85 | 332,769 | 2026-04-21 | Filing | |
| $0.50 | 6,000,000 | $3,000,000.00 | 17,652,466 | 2023-09-26 | Filing | |
| $5.27 | 100,000 | $526,520.00 | 23,652,466 | 2022-08-30 | Filing | |
| $5.33 | 400,000 | $2,130,720.00 | 23,752,466 | 2022-08-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 400,000 | $22,000 | 0% | |
| 2. | 373,200 | $20,152 | 0% | |
| 3. | 365,600 | $19,706 | 0% | |
| 4. | 244,300 | $13,168 | 0% | |
| 5. | 105,300 | $5,686 | 0% |
News See All
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update
Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO) share price has underperformed over the past year, down nearly 64%.
10 Stocks Under $1 That Will Explode
U.S. equity markets are beginning their 2026 journey without taking a major break from existing trends, according to Morgan Stanley CIO and chief U.S.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2025 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2025 Earnings Call Transcript November 6, 2025Sangamo Therapeutics, Inc. misses on earnings expectations.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2025 Teleconference Call. Please be advised that today's conference is being recorded.
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy
Sangamo Therapeutics Inc. (NASDAQ:SGMO) is one of the best penny stocks under $1 to buy now.
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data
Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call. Please be advised that today's conference is being recorded.
Hedge Fund Resource Center